Abstract
Despite years of investigation, breast cancer remains a major cause of death worldwide. Phage display is a powerful molecular method in which peptide and protein libraries can be displayed via genetic fusions on the surface of phages. This approach has tremendous potential for biomedical applications and has already facilitated the discovery of specific antibodies, specific antigens, and peptides with potential roles in the diagnosis and treatment of malignancies including breast cancer. In this review, we discuss the new and the latest advancements in the applications of the phage display technique in the provision of immune therapeutics for breast cancer.
Keywords: Bacteriophage, phage display, breast cancer, immune therapeutics, peptide library, vaccine.
Current Pharmaceutical Design
Title:Phage-based Nanomedicines as New Immune Therapeutic Agents for Breast Cancer
Volume: 24 Issue: 11
Author(s): Atefeh Arab, Rezvan Yazdian Robati, Jessica Nicastro, Roderick Slavcev and Javad Behravan*
Affiliation:
- School of Pharmacy, University of Waterloo, 200 University Ave, Waterloo,Canada
Keywords: Bacteriophage, phage display, breast cancer, immune therapeutics, peptide library, vaccine.
Abstract: Despite years of investigation, breast cancer remains a major cause of death worldwide. Phage display is a powerful molecular method in which peptide and protein libraries can be displayed via genetic fusions on the surface of phages. This approach has tremendous potential for biomedical applications and has already facilitated the discovery of specific antibodies, specific antigens, and peptides with potential roles in the diagnosis and treatment of malignancies including breast cancer. In this review, we discuss the new and the latest advancements in the applications of the phage display technique in the provision of immune therapeutics for breast cancer.
Export Options
About this article
Cite this article as:
Arab Atefeh , Robati Yazdian Rezvan, Nicastro Jessica, Slavcev Roderick and Behravan Javad *, Phage-based Nanomedicines as New Immune Therapeutic Agents for Breast Cancer, Current Pharmaceutical Design 2018; 24 (11) . https://dx.doi.org/10.2174/1381612824666180327152117
DOI https://dx.doi.org/10.2174/1381612824666180327152117 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Laboratory Techniques for Human Viral Encephalitis Diagnosis
Infectious Disorders - Drug Targets Bevacizumab and Angiogenesis Inhibitors in the Treatment of CNS Metastases: The Road less Travelled
Current Molecular Pharmacology Exogenous Hormonal Regulation in Breast Cancer Cells by Phytoestrogens and Endocrine Disruptors
Current Medicinal Chemistry Molecular Players at the Intersection of Obesity and Osteoarthritis
Current Drug Targets Time Recall; Future Concept of Chronomodulating Chemotherapy for Cancer
Current Pharmaceutical Biotechnology Interaction of Endocannabinoid Receptors with Biological Membranes
Current Medicinal Chemistry Editorial from Editor-in-Chief
Current Medical Imaging The Clinical Applications of Heat Shock Protein Inhibitors in Cancer - Present and Future
Current Cancer Drug Targets Crohns Targeted Therapy: Myth or Real Goal?
Current Drug Discovery Technologies Lymphatic Targeting of Nanosystems for Anticancer Drug Therapy
Current Pharmaceutical Design Chronic Inflammation in the Pancreas and Salivary Glands - Lessons from Similarities and Differences in Pathophysiology and Treatment Modalities
Current Pharmaceutical Design Biology and Impact of Signal Transducers and Activators of Transcription and Their Regulators as Targets in Cancer Therapy
Current Signal Transduction Therapy The Management of Metastatic Bone Disease with the Combination of Bisphosphonates and Radiotherapy: From Theory to Clinical Practice
Anti-Cancer Agents in Medicinal Chemistry Neuropeptides as Therapeutic Approach to Autoimmune Diseases
Current Pharmaceutical Design Estrogen Receptors: Molecular Interactions, Virtual Screening and Future Prospects
Current Topics in Medicinal Chemistry MicroRNA and Cancer: Tiny Molecules with Major Implications
Current Genomics <i>In Vitro</i> and <i>In Vivo</i> Evaluation of Novel DTX-Loaded Multifunctional Heparin-Based Polymeric Micelles Targeting Folate Receptors and Endosomes
Recent Patents on Anti-Cancer Drug Discovery Meet Our Regional Editor
MicroRNA Synthesis of New Antibacterial Cubane-based Nanocomposite and its Application in Combination Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Advances and Challenges in the Use of Nanoparticles to Optimize PK/PD Interactions of Combined Anti-Cancer Therapies
Current Drug Metabolism